Where is Progenity located?

Progenity is located in San Diego, United States .

Who is the current CEO of Progenity?

Harry Stylli is the current CEO of Progenity.

How many employees does Progenity have?

Progenity has 125 employees as of Dec 31, 2022.

When was the latest funding round of Progenity?

Progenity's latest funding round was on May 11, 2021.

What is the annual revenue of Progenity?

Annual revenue of Progenity is $1.25M as on Dec 31, 2021.

Where does Progenity rank among its competitors?

Progenity ranks 5 amongst 96 active competitors.

Who are the top competitors of Progenity?

Progenity's top competitors are Natera, BillionToOne and SYNLAB.

Progenity - 2025 Company Profile, Team, Funding, Competitors & Financials

Progenity is a public company based in San Diego (United States), founded in 2011 by . It operates as a Provider of non invasive prenatal genomic testing. Progenity has raised $217M in funding from Athyrium Capital Management. The company has 96 active competitors, including 12 funded and 17 that have exited. Its top competitors include companies like Natera, BillionToOne and SYNLAB.

Company Details

Provider of non-invasive prenatal genomic testing. The company's diagnostic platform is based on genomics, epigenomics, proteomics, and metabolomics. The company's products include a Preparent carrier test for prenatal genetic disorders, an Innatal prenatal screen for chromosomal-related disorders, hereditary cancer risk prediction, and Resura prenatal test for detecting monogenic disorders. The company also developing precision medicine for prenatal, perinatal, oncology, and gastroenterology diseases.

Website
Social
Email ID: @progenity.com
Registered Address: San Diego, California

Key Metrics

Founded Year

2011

Location

San Diego, United States

Stage

Public

Total Funding

in 9 rounds

Latest Funding Round

Investors

Athyrium Capital Management & 2 more

Ranked

5^th among

Annual Revenue

as on Dec 31, 2021

Employee Count

as on Dec 31, 2022

Investment & Acquisitions

Carmenta Bio

Similar Companies

Natera &

Exit Details

Public

Progenity is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CIN: 1580063 United States, Active	Jan 08, 2012	$1.25M (as on Dec 31, 2021)	54 (as on Dec 31, 2022)	-
CIN: 273950390 United States, Active	Dec 31, 1999	-	125 (as on Dec 31, 2022)	-

Get your free copy of Progenity's company profile

Progenity has raised a total funding of $217M over 9 rounds. Its first funding round was on Jun 12, 2013.

Progenity has 3 institutional investors including Athyrium Capital Management, and .

Here is the list of recent funding rounds of Progenity:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
May 11, 2021	$40M	Post IPO	9403055	3222784	-
Feb 23, 2021	Undisclosed	Post IPO	8321256	9751587	-
Dec 02, 2020	$75M	Post IPO	9027540	4077400	-

Access funding benchmarks and valuations. Sign up today!

View details of Progenity's funding rounds and investors

The founders of Progenity is . is the CEO of Progenity.

Here are the details of Progenity's key team members:

: Founder & CEO of Progenity.
Contact Info:

View details of

Progenity's employee count trend

Progenity has 125 employees as of Dec 22. The total employee count is 74.0% lower than what it was in Dec 21. Here is Progenity's employee count trend over the years:

Uncover Progenity's growth story! Sign up today!

Access 秘密研究所 on any website

Our Google Chrome extension lets you view company details while browsing their websites

Top competitors of Progenity include Natera, BillionToOne and SYNLAB. Here is the list of Top 10 competitors of Progenity, ranked by 秘密研究所 score:

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women鈥檚 health, and organ health	$152M	Sofinnova Investments, Foresite Capital听&补尘辫;听	73/100
2nd	BillionToOne 2015, San Francisco (United States), Series D	Provider of cell-free cancer liquid biopsy test	$389M	Adams Street Partners, Baillie Gifford听&补尘辫;听	62/100
3rd	SYNLAB 1998, Munich (Germany), Public	Provider of medical diagnosis and clinical laboratory analysis services	-	SVG Capital, BC Partners听&补尘辫;听	56/100
4th	Beikang Medical 2010, Suzhou (China), Public	Developer of NGS-based diagnostic solutions for neonatal	$36.5M	Genesis Capital, Broad Vision Funds听&补尘辫;听	54/100
5th	Progenity 2011, San Diego (United States), Public	Provider of non invasive prenatal genomic testing	$217M	Athyrium Capital Management, TRITON FUNDS听&补尘辫;听	54/100
6th	Pictor 2005, Auckland (New Zealand), Series A	Developer of immunodiagnostic products based on multiplexed assays	$11.1M	New Zealand Growth Capital Partners, Cure Kids Ventures听&补尘辫;听	53/100
7th	IdentifAI 2020, Tel Aviv (Israel), Series A	Provider of a non-invasive prenatal screening test for genetic syndromes	$9.8M	eHealth Ventures听&补尘辫;听	50/100
8th	Sequenom 1994, San Diego (United States), Acquired	Provider of noninvasive prenatal testing using circulating cell-free fetal nucleic acids	-	SR One, Star Ventures听&补尘辫;听	45/100
9th	Berry Genomics 2010, Beijing (China), Public	Provider of genetic testing products and tests	$16M	Legend Star, Legend Capital听&补尘辫;听	45/100
10th	Nonacus 2015, Birmingham (United Kingdom), Unfunded	Provider of technology and services for genomic healthcare	-	-	44/100